Upon serial acquisition of mutations, ARCH/CHIP can progress to myelodysplastic syndrome (MDS) and ultimately acute myeloid leukemia (AML), directly to AML without an intervening MDS stage, or to other conditions such as myeloproliferative neoplasms (MPN) or lymphoid neoplasms [70, 72]. The gene discussed is TSLIG1; the disease is myeloproliferative disorder.